Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (type) |
||
| Line 5: | Line 5: | ||
<ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | <ref>[http://www.impactjournals.com/oncotarget/misc/linkedout.php?pii=4528 Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis]</ref> | ||
ursodeoxycholic acid and bezafibrate are under | ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure) | ||
<references/> | <references/> | ||
Revision as of 00:12, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure)